Country: Bandaríkin
Tungumál: enska
Heimild: NLM (National Library of Medicine)
FLUPHENAZINE DECANOATE (UNII: FMU62K1L3C) (FLUPHENAZINE - UNII:S79426A41Z)
Hikma Pharmaceuticals USA Inc.
FLUPHENAZINE DECANOATE
FLUPHENAZINE DECANOATE 25 mg in 1 mL
INTRAMUSCULAR
PRESCRIPTION DRUG
Fluphenazine Decanoate Injection, USP is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). Fluphenazine Decanoate Injection, USP has not been shown effective in the management of behavioral complications in patients with mental retardation. Phenothiazines are contraindicated in patients with suspected or established subcortical brain damage. Phenothiazine compounds should not be used in patients receiving large doses of hypnotics. Fluphenazine decanoate injection is contraindicated in comatose or severely depressed states. The presence of blood dyscrasia or liver damage precludes the use of fluphenazine decanoate. Fluphenazine decanoate is not intended for use in children under 12 years of age. Fluphenazine decanoate injection is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross-sensitivity to phenothiazine derivatives may occur.
Fluphenazine Decanoate Injection, USP, 25 mg/mL is available in 5 mL multiple dose vials, packaged in individual cartons. NDC 0143-9529-01. Protect from light. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]; avoid freezing and excessive heat. To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . For Product Inquiry call 1-877-845-0689.
Abbreviated New Drug Application
FLUPHENAZINE DECANOATE- FLUPHENAZINE DECANOATE INJECTION HIKMA PHARMACEUTICALS USA INC. ---------- FLUPHENAZINE DECANOATE INJECTION, USP RX ONLY WARNING INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patient is not clear. Fluphenazine decanoate injection is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS). DESCRIPTION Fluphenazine decanoate is the decanoate ester of a trifluoromethyl phenothiazine derivative. It is a highly potent behavior modifier with a markedly extended duration of effect. Fluphenazine Decanoate Injection, USP is a sterile injection, available for intramuscular or subcutaneous administration, providing 25 mg fluphenazine decanoate per mL in a sesame oil vehicle with 1.2% (w/v) benzyl alcohol as a preservative. At the time of manufacture, the air in the vials is replaced by nitrogen. The chemical name of fluphenazine decanoate is 4-[3-[2-(Trifluoromethyl)-10_H_- phenothiazin-10-yl]propyl]-1-piperazineethanol Lestu allt skjalið